Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and montanide ISA 51 for patients with resected stages III and IV melanoma

Journal of Clinical Oncology

Volumn 23, Issue 4, 2005, Pages 741-750

  Sanderson, Kristin ^a   Scotland, Ronald ^a   Lee, Peter ^a   Liu, Dongxin ^a   Groshen, Susan ^a   Snively, Jolie ^a   Sian, Shirley ^a   Nichol, Geoffrey ^a   Davis, Thomas ^a   Keler, Tibor ^a   Yellin, Michael ^a   Weber, Jeffrey ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR9; CORTICOSTEROID; DEXAMETHASONE; FREUND ADJUVANT; GLYCOPROTEIN GP 100; IPILIMUMAB; MELAN A; MONOPHENOL MONOOXYGENASE; MONTANIDE ISA 51; OPIATE; PREDNISOLONE; UNCLASSIFIED DRUG; CANCER VACCINE; CHEMOKINE RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T-LYMPHOCYTE ANTIGEN 4; DIFFERENTIATION ANTIGEN; DRUG DERIVATIVE; GPR 9 6 RECEPTOR; GPR-9-6 RECEPTOR; LEUKOCYTE ANTIGEN; MANNITOL; MART1 ANTIGEN; MELANOCYTE LINEAGE SPECIFIC ANTIGEN GP100; MELANOCYTE LINEAGE-SPECIFIC ANTIGEN GP100; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; OLEIC ACID; PEPTIDE FRAGMENT; TUMOR ANTIGEN; TUMOR PROTEIN;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ADJUVANT THERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ANXIETY; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNITY; BILIRUBIN BLOOD LEVEL; BLEPHARITIS; BLOODY DIARRHEA; BLURRED VISION; CANCER STAGING; CANCER SURGERY; CHILL; CLINICAL ARTICLE; COLITIS; CONFUSION; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DIARRHEA; DISORIENTATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRY SKIN; EDEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; EYE TOXICITY; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GRANULOMA; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOLOGY; INFLAMMATION; INJECTION SITE DESQUAMATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE RASH; INJECTION SITE SWELLING; INSOMNIA; JOINT STIFFNESS; LACTATE DEHYDROGENASE BLOOD LEVEL; LETHARGY; LEUKAPHERESIS; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MELANOMA; MELENA; MYALGIA; NAUSEA; PALLIATIVE THERAPY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHOTOSENSITIVITY; PRIORITY JOURNAL; RECTUM INFLAMMATION; RETINA PIGMENT DEGENERATION; RIGOR; SIDE EFFECT; SWEATING; UVEITIS; VISUAL IMPAIRMENT; VITILIGO; VITREOUS BODY DETACHMENT; VOMITING; FLOW CYTOMETRY; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; VACCINATION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION; ANTIGENS, NEOPLASM; AUTOIMMUNITY; CANCER VACCINES; FEMALE; FLOW CYTOMETRY; HUMANS; MALE; MANNITOL; MELANOMA; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MONOPHENOL MONOOXYGENASE; NEOPLASM PROTEINS; NEOPLASM STAGING; OLEIC ACIDS; PEPTIDE FRAGMENTS; RECEPTORS, CHEMOKINE; VACCINATION;

EID: 20044395957     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.01.128     Document Type: Article

References (38)

1. van der Merwe PA, Davis SJ: Molecular interactions mediating T cell antigen recognition. Annu Rev Immunol 21:659-684, 2003
2. Davis SJ, Ikemizu S, Evans EJ, et al: The nature of molecular recognition by T cells. Nat Immunol 4:217-224, 2003
3. Thompson CB, Allison JP: The emerging role of CTLA-4 as an immune attenuator. Immunity 7:445-450, 1997
4. + regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 192:303-310, 2000
5. Salomon B, Bluestone JA: Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu Rev Immunol 19:225-252, 2001
6. Waterhouse P, Pennington JM, Timms E, et al: Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 270:985-988, 1995
7. Perez VL, van Parijs L, Biuckians A, et al: Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. Immunity 6:411-417, 1997
8. + T cell- and IL-2-dependent mechanism. Immunity 11:483-493, 1999
9. Tivol EA, Borriello F, Schweiter AN, et al: Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3:541-547, 1995
10. Bachmann MF, Gallimone A, Jones E, et al: Normal pathogen-specific immune responses mounted by CTLA-4-deficient T cells: A paradigm reconsidered. Eur J Immunol 31:450-458, 2001
11. Yu X, et al: The role of B7 costimulation in CD4/CD8 T cell homeostasis. J Immunol 164: 3543-3553, 2000
12. Prlic M, et al: Homeostatic expansion occurs independently of costimulatory signals. J Immunol 167:5664-5668, 2001
13. Alegre ML, Sheis H, Thompson CB, et al: Expression and function of CTLA-4 in Th1 and Th2 cells. J Immunol 161:3347-3356, 1998
14. Huang AY, Golumbek P, Ahmadzadeh M, et al: Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264:961-965, 1994
15. Davila E, Kennedy R, Celis E: Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade. Cancer Res 63:3281-3288, 2003
16. van Elsas A, Sutmuller RP, Hurwitz AA, et al: Elucidating the autoimmune and anti-tumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 (CTLA-4) blockade in combination with a B16 melanoma vaccine: Comparison of prophylaxis and therapy. J Exp Med 194:427-438, 2001
17. Lee P, Wang F, Kuniyoshi J, et al: Effects of interleukin-12 on the immune response to a multi-peptide vaccine for resected metastatic melanoma. J Clin Oncol 19:3836-3847, 2001
18. Altman J, Moss PAH, Goulder P, et al: Phenotypic analysis of antigen specific T lymphocytes. Science 274:94-96, 1996
19. Weber J, Sondak VK, Scotland R, et al: Granulocyte-macrophage-colony- stimulating factor added to a multipeptide vaccine for resected stage II melanoma. Cancer 97:186-200, 2003
20. Pullarkat V, Lee PP, Scotland R, et al: A phase I trial of SD-9427 (progenipoietin) with a multipeptide vaccine for resected metastatic melanoma. Clin Cancer Res 4:1301-1312, 2003
21. Perrey C, Turner SJ, Pravica V, et al: ARMS-PCR methodologies to determine IL-10, TNF-alpha, TNF-beta and TGF-beta 1 gene polymorphisms. Transpl Immunol 7:127-128, 1999
22. Camacho LM, Ribas A, Glaspy JA, et al: Phase I trial of human CTLA-4 monoclonal antibody CP-675,206 in patients with advanced solid malignancies. Proc Am Soc Clin Oncol 23:164, 2004 (abstr 2505)
23. Dranoff G, Jaffee E, Lazenby A, et al: Vaccination with irradiated tumor cells engineered to secrete GM-CSF stimulates potent, specific, and long lasting anti-tumor immunity. Proc Natl Acad Sci U S A 90:3539-3543, 1993
24. Hurwitz AA, Yu TF, Leach DR, et al: CTLA-4 blockade synergizes with tumor-derived GM-CSF for treatment of an experimental mam-carcinoma. Proc Natl Acad Sci U S A 95:10067-10071, 1998
25. Hurwitz AA, et al: Combination immunotherapy of primary prostate cancer in a transgenic model using CTLA-4 blockade. Cancer Res 60:2444-2448, 2000
26. Espenschied J, Lamont J, Longmate J, et al: CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model. J Immunol 170:3401-3407, 2003
27. Walker LS, Ausubel LJ, Chodos A, et al: CTLA-4 differentially regulates T cell responses to endogenous tissue protein versus exogenous immunogen. J Immunol 169:6202-6209, 2002
28. van Elsas A, Hurwitz AA, Allison JP: Combination immunotherapy of B16 melanoma using anti-CTLA-4 and GM-CSF producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med 190:355-366, 1999
29. Rosenberg SA, White DE: Vitiligo in patients with melanoma: Normal tissue antigens can be targets for cancer immunotherapy. J Immunother 19:81-84, 1996
30. + regulatory T cells in anti-tumor therapy reveals alternative pathways for suppression of auto-reactive CTL responses. J Exp Med 194:823-832, 2001
31. Phan GQ, Yang JC, Sherry RM, et al: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 100:8372-8377, 2003
32. Tchekmedyian S, Glasby J, Korman A, et al: MDX-010 (human anti-CTLA4): A phase I trial in malignant melanoma. Proc Am Soc Clin Oncol 21:223, 2002 (abstr 56)
33. Hodi FS, Mihm MC, Soiffer RJ, et al: Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 100:4712-4717, 2003
34. Hersh E, Weber J, Powderly J, et al: A phase II randomized multi center study of MDX-010 alone or in combination with dacarbazine (DTIC) in stage IV metastatic malignant melanoma. Proc Am Soc Clin Oncol 23:709, 2004 (abstr 7511)
35. Ueda H, Howson JM, Esposito L, et al: Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423:506-511, 2003
36. 368-376 (37OD) +/- alpha-IFN +/- GM-CSF. Proc Am Soc Clin Oncol 23:707, 2004 (abstr 7502)
37. Papadakis KA, Landers C, Prehn J, et al: CC chemokine receptor 9 expression defines a subset of peripheral blood lymphocytes with mucosal T cell phenotype and Th1 or T-regulatory 1 cytokine profile. J Immunol 171: 159-165, 2003
38. Watanabe N, Gavrieli M, Sedy JR, et al: BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 4:670-679, 2003